Fermenta Biotech Limited (FERMENTA) reports Q2 FY27 results with revenue up 8% QoQ to INR 135.8 crore and EBITDA up 3% QoQ.
Sai Life Sciences Limited (NSE: SAILIFE) reports Q2 FY27 revenue growth of 23% YoY, maintaining strong EBITDA margin.
AstraZeneca Pharma India Limited reports 30% growth in Q2 FY26-27 with INR 7,291 Mn revenue, driven by strong commercial performance.
Fortis Healthcare Limited (FORTIS) reports consolidated revenues of INR 2,735 Cr for Q2 FY27, up 17.3%, with a PAT margin of 11.7%.
GPT Healthcare Limited (NSE: GPTHEALTH) reports a 16.5% YoY increase in total income for H1 FY27, driven by strong operational metrics.
Windlas Biotech Limited (WINDLAS) reports H1 & Q2 FY27 results with record revenue of Rs. 512 crores, 18% YoY growth, and strong profitability metrics.
Windlas Biotech Limited (WINDLAS) reports a 19% YoY revenue growth to Rs. 264 crore in Q2 FY27, driven by strong performance across all business verticals.
